Bank of America Corp DE increased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) by 36.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 639,632 shares of the medical instruments supplier's stock after purchasing an additional 171,554 shares during the period. Bank of America Corp DE's holdings in West Pharmaceutical Services were worth $262,703,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of WST. ARK Investment Management LLC acquired a new stake in West Pharmaceutical Services in the 1st quarter valued at approximately $179,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in West Pharmaceutical Services in the 1st quarter valued at approximately $4,412,000. National Asset Management Inc. raised its position in West Pharmaceutical Services by 11.9% in the 1st quarter. National Asset Management Inc. now owns 2,269 shares of the medical instruments supplier's stock valued at $933,000 after buying an additional 241 shares during the last quarter. Kestra Advisory Services LLC raised its position in West Pharmaceutical Services by 7.5% in the 1st quarter. Kestra Advisory Services LLC now owns 3,124 shares of the medical instruments supplier's stock valued at $1,283,000 after buying an additional 219 shares during the last quarter. Finally, Mutual of America Capital Management LLC raised its position in West Pharmaceutical Services by 1.1% in the 1st quarter. Mutual of America Capital Management LLC now owns 9,904 shares of the medical instruments supplier's stock valued at $4,068,000 after buying an additional 104 shares during the last quarter. Institutional investors own 91.98% of the company's stock.
Get
West Pharmaceutical Services alerts:
West Pharmaceutical Services Stock Up 0.7 %
Shares of West Pharmaceutical Services stock opened at $269.93 on Tuesday. The business's 50 day simple moving average is $312.53 and its 200 day simple moving average is $330.25. West Pharmaceutical Services, Inc. has a 52-week low of $261.31 and a 52-week high of $475.00. The firm has a market cap of $19.99 billion, a PE ratio of 29.96, a P/E/G ratio of 1.08 and a beta of 1.18. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.41 and a current ratio of 3.13.
West Pharmaceutical Services (NYSE:WST – Get Rating) last announced its earnings results on Thursday, July 28th. The medical instruments supplier reported $2.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.19 by $0.28. West Pharmaceutical Services had a return on equity of 29.08% and a net
margin of 23.41%. The business had revenue of $771.30 million for the quarter, compared to analyst estimates of $754.25 million. During the same quarter last year, the firm earned $2.46 EPS. West Pharmaceutical Services's revenue for the quarter was up 6.6% compared to the same quarter last year. On average, analysts predict that West Pharmaceutical Services, Inc. will post 9.09 earnings per share for the current fiscal year.
Insider Buying and Selling
In other West Pharmaceutical Services news, insider Silji Abraham sold 5,374 shares of the company's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $343.93, for a total transaction of $1,848,279.82. Following the sale, the insider now directly owns 3,201 shares of the company's stock, valued at $1,100,919.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.60% of the stock is owned by corporate insiders.
About West Pharmaceutical Services
(Get Rating)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Featured Articles
- Get a free copy of the StockNews.com research report on West Pharmaceutical Services (WST)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
